Concurrent Workshop Sessions – Ballrooms A & B

Workshop 1: Global Product Launch

This workshop will discuss, debate and analyse the practicalities of global launch....Do you?

• Start close to home in Asia?
• Or go first to the largest worldwide market, the United States?
• Or are the UK and Europe the best starting places– Medica is a good place to find distributors?

What are the key issues/strategies needed for Global Product Launch?
How to select the best channel & support, motivate and manage the supply chain?
Do we need a local office?

Session Chair: Carol Upton; CEO, Upton Consulting

Session Speakers:

• Martin Dillon; General Manager Sales and Marketing, Polartechnics Limited
• Ross Harricks; Founder, AtCor Medical; Director, Ventracor
• Andrew McLellan; Business Unit Manager, Leica BioSystems Pty Ltd
• Mark Verschuur; Managing Director, Fairmont Medical Pty Ltd

Workshop 2: Financing Growth of Medical Technology Companies

Financing the start up and growth of medical technology businesses is a major challenge for company founders and managers. Whilst there are a number of financing alternatives, access to adequate amount of capital is one of the major barriers to success in commercialising Australian medical technology innovation.

This workshop will address the typical lifecycle of medical technology companies and the sources of funding available at each stage. It will provide an overview of the funding challenges through an actual company case study putting forward both the perspective of the founder/management and investors.

Types of funding that will be discussed are;

• Angel
• Venture capital
• Partnering
• Initial Public Offering (IPO)
• Grant support

Session Chair: Dr Mike Skalsky; Managing Director, Sci2Rx Pty Ltd

Panel:

• Prof Michael Vitale; Monash Asia-Pacific Centre for Science and Wealth Creation
• Dr Ron Sekel OAM; Chief Technical Officer and Director of Portland Orthopaedics
• Dr Richard Gregson; Director of Portland Orthopaedics, and partner of Equity Partners
• Brookes McTavish; Managing Director, Australian Small Scale Offerings Board Limited
• Dr Phillip Wing; Executive Chairman, Kirin Corporation; Co- Founder and Chairman, Applied Physiology

Workshop 3: Mentoring for Medical Technology Businesses:

“Small Sins cast Long Shadows”  AKA “Cellar or Stellar”, a corporate saga in 4 acts.

A simulated case study has been prepared for active dissection by all members attending this session. Within the membership of the attendees of the session will be experts in company structure, corporate governance, Intellectual Property, Investment, Project Management, General Management, International Sales and Marketing, Regulatory Approvals and more.

The thrust of this session is to show the development of a medical device company through a number of stages and illustrate how decisions made at one stage impact, both positively and negatively, on the progress through other stages.

All of us have committed some of these “Sins” and collectively we would like to explore how the corrections were made and why. Come prepared with pencil and paper, as well as experience and better judgment.

Moderator: Peter Taylor; VPatch Medical Systems

Panel:

• Luke Whelan; Managing Director, Eqipmed
• Michael Squires; Partner, Phillips Ormonde Fitzpatrick
• Ben McGlaughlin; Partner, Baker & McKenzie
• Prof Michael Vitale; Commercialisation Department of Monash University and Wealth Creation
• Dr Derrick Beech; Consultant, Medical Technology Consulting
• Theo Afkoudias; Director, Business Plans

Workshop 4: Medical Devices Regulatory Affairs

• Post October 2007 - TGAs new business processes for medical devices regulation.

Presenting:

• Dr Larry Kelly; Director Office of Blood Devices and Tissues, Therapeutic Goods Administration
• Judy Develin; Project Director, Business Improvement Program, Therapeutic Goods Administration

Regs to Riches - the regulatory life cycle of a medical device
A hypothetical to both inform and entertain.  A panel of government and industry experts will explore regulatory requirements for a medical device – from invention through clinical trials, product approval and post market monitoring. 

Panel:

• Shelley Tang; Head of Medical Devices Assessment Section, Therapeutic Goods Administration
• Pam Carter; Head of Market Vigilance and Monitoring Section, Therapeutic Goods Administration
   

Chair and Moderator: Arthur Brandwood; Managing Director, Brandwood Biomedical

Stream 1: Session 1;
Early Stage Medtech Company

There is more to Medical Technology Companies than the market need/technology, what are some of the key attributes to a successful business and how do you get them in your business?

• Why is a business plan so important for managing and growing a Medtech Company?
• Why are Directors so important? How to find candidates and which ones to select
• IP Strategy: How do you effectively manage and protect valuable IP?
• Tips for managing cash flow in small to medium Medtech's

Session Chair: Richard Gough; Partner, Intellectual Property, Baker & McKenzieSession

Session Speakers:

• Maria Pawelek; Senior Associate, Baker & McKenzie
• Elisabeth Coffey; Senior Associate, Baker & McKenzie
• Lachlan James
• David McCarthy; Partner, Deloitte Touche Tohmatsu 

Sponsored by Baker & McKenzie

Stream 2: Session 1;
Growing a Global Medtech Company

Product has been launched into the Global Marketplace, now how do you grow and succeed – the world is a big place

• Strategic Alliances -what to do to make them work
• Managing the global company
• Resmed case study - how to create & sustain the product supply stream; what is done locally vs. centrally; how to meet changing global demands
  

Session Chair: Dr Mike Hirshorn OAM; Director, Kestrel Capital Pty Ltd

Session Speakers:

• Dr Daniel Grant; Head of Strategic Alliances, Pfizer Australia
• Rob Douglas; Chief Operating Officer, Resmed Ltd

Stream 1: Session 2
Regulated Product Development

Introduction: A proven process for managing your development project for Regulatory Approval.

• Planning your Development - Keys to launching into your development program.
• Getting from idea to successful product - benefits of a good requirements process
• Effective Design Control through your Development to prepare for Conformity Assessment.

Session Chair: Andreas Knaack; Director, Instrument Design & Development, Invetech.

This will provide key context for three speakers to expand on specific process activities to establish a successful end-toend development project.

Session Speakers:

• Jefferson Harcourt; Managing Director, Grey Innovation
• Rick Gardner; Program Manager, Invetech
• Stephen Marshall; CEO, Perficio

Sponsored by Invetech 
 

Stream 2: Session 2
Global Marketing- more than just ads & brochures!

• The importance of global clinical trials and reimbursement strategies
• A customer focussed approach to global marketing includes: market research & product definition; global vs. local marketing- getting the balance correct
• How to optimize the global marketing mix & track its effectiveness.
   

Session Chair: Dr Derrick Beech; Consultant, Medical Technology Consulting

Session Speakers:

• Brad Sheehan; Consultant, Medical Technology Consulting
• Michael Kavanagh; Senior Vice President, Global Marketing, Cochlear Ltd
• Andrew McLellan; Business Unit Manager, Vision BioSystems Pty Ltd

Session 3: War stories;

Come and listen to some of the interesting stories from a selection of our local industry. Each will present a particular perspective on a problem that confronted their business and their strategy to address the issue and its success.  

Session Chair: Dr Greg Roger; CEO, Advanced Surgical Design & Manufacture Ltd

Session Speakers:

• Ben Dillon; CEO, Polartechnics Limited
• Paul Coffey; COO, BMDI TUTA
• Vicki Tutungi; CEO, Optiscan Imaging

Session 4: Future Technologies;

Hear from the experts about future technologies that will solve the intractable clinical problems of today.

Session Chair: Prof Anne Simmons; Head of School, Graduate School of Biomedical Engineering, University of New South Wales

Session Speakers:

• Dr Charles Lindall; Commercial Manager, CSIRO
• David Young; Managing Director, Fermiscan Holdings Ltd
• Dr Darren Martin; R&D Group Leader, The Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland